



Cumberland Pharmaceuticals to Present at the UBS Global Life Sciences Conference in New York

NASHVILLE, Tenn., Sept 13, 2010 /PRNewswire via COMTEX News Network/ -- **Cumberland Pharmaceuticals Inc.** (Nasdaq: CPIX), a specialty pharmaceutical company focused on hospital acute care and gastroenterology markets, today announced that it will present a corporate overview at the UBS Global Life Sciences Conference at the Grand Hyatt New York on Monday, September 20, 2010, at 12:00 p.m. Eastern Time.

The presentation will be simultaneously webcast and can be accessed by visiting the Investor Relations section of Cumberland Pharmaceuticals' website at www.cumberlandpharma.com.

Shortly following the live webcast a replay will also be available on the Company's website.

About Cumberland Pharmaceuticals

Cumberland Pharmaceuticals Inc. is a Tennessee-based specialty pharmaceutical company focused on the acquisition, development and commercialization of branded prescription products. The Company's primary target markets include hospital acute care and gastroenterology. Cumberland markets Acetadote(R) for the treatment of acetaminophen poisoning, Caldolor (R), the first injectable treatment for pain and fever approved in the United States, and Kristalose(R), a prescription laxative. Cumberland is dedicated to providing innovative products which improve quality of care for patients. For more information on Cumberland Pharmaceuticals, please visit the Company website at www.cumberlandpharma.com.

Contact:

Angela Novak
Investor Relations
(615) 255-0068
investors@cumberlandpharma.com

SOURCE Cumberland Pharmaceuticals Inc.

Copyright (C) 2010 PR Newswire. All rights reserved